Start by confirming what the product is
FDA’s Center for Veterinary Medicine regulates new animal drugs in the United States. Sponsors should first determine whether the intended use and claims make the product a drug and which pathway may apply. FDA provides an Ask CVM contact for companies that are unsure how a product will be classified.
This early classification work matters because a supplement, device, biologic and new animal drug do not follow identical systems.
The INAD file supports development
For pioneer new animal drugs, FDA describes the Investigational New Animal Drug file as the framework under which studies supporting safety and effectiveness can be conducted and submitted. The agency recommends phased review so technical sections can be discussed and reviewed incrementally.
For startups, this structure can translate into financing milestones. Completion of a meaningful technical section may reduce uncertainty even before final approval.
A NADA assembles the approval case
A New Animal Drug Application supports approval of a new animal drug. FDA reviews evidence related to safety, effectiveness, manufacturing and labeling. Food-producing animal products can add human food-safety requirements.
A strong development plan aligns the target product profile, clinical study design, manufacturing strategy and proposed label so the evidence package tells one coherent story.
Conditional approval is specific, not automatic
FDA also provides a conditional approval pathway for qualifying products. Conditional approval is not a shortcut that eliminates the need for safety or manufacturing work; it addresses the effectiveness standard under defined eligibility conditions and requires continuing evidence collection.
Founders should discuss eligibility and evidence expectations with FDA rather than build a financing plan around assumptions.
Primary resources
- FDA – How to Get a New Animal Drug Approved
- FDA – New Animal Drug Applications